XNAS · Healthcare · Health Information Services
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -0.57 | -0.63 | -10.35% | $58.6M | ❌ Miss | -5.67% | -1.40% | — |
| 2026-02-25 | Q4 2025 | -0.11 | -0.19 | -72.73% | $87.2M | ❌ Miss | -0.17% | +11.19% | -6.10% |
| 2025-11-05 |
| Q3 2025 |
| -0.73 |
| -0.57 |
| +21.92% |
| $54.3M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.72 | -0.65 | +9.72% | $54.8M | ✅ Beat | +5.02% | +2.59% | -1.09% |
| 2025-02-26 | Q4 2024 | -0.38 | -0.24 | +36.84% | $88.3M | ✅ Beat | +2.53% | +0.65% | -8.02% |
| 2024-11-12 | Q3 2024 | -0.60 | -0.87 | -45.00% | $35.3M | ❌ Miss | -0.72% | -14.92% | -5.30% |
| 2024-07-31 | Q2 2024 | -0.85 | -0.66 | +22.35% | $47.3M | ✅ Beat | +1.44% | -18.99% | -5.61% |
| 2024-05-01 | Q1 2024 | -0.75 | -0.86 | -14.67% | $36.6M | ❌ Miss | -8.19% | -8.08% | -14.81% |
Showing last 8 quarters.